Osteopontina, una proteína involucrada en la progresión tumoral, y su participación en el desarrollo del carcinoma colorrectal.

Autores:
Becerra, Daniel
Benedetti, Ines
Tipo de recurso:
Article of journal
Fecha de publicación:
2019
Institución:
Universidad de Cartagena
Repositorio:
Repositorio Universidad de Cartagena
Idioma:
spa
OAI Identifier:
oai:repositorio.unicartagena.edu.co:11227/12866
Acceso en línea:
https://doi.org/10.32997/rcb-2018-2711
Palabra clave:
Osteopontin
Colorectal neoplasms
Immunohistochemistry
Osteopontina
Neoplasias colorrectales
Inmunohistoquímica
Rights
openAccess
License
Revista Ciencias Biomédicas - 2018
id UCART2_e40defd55053ef7b26eb6dfe234a5829
oai_identifier_str oai:repositorio.unicartagena.edu.co:11227/12866
network_acronym_str UCART2
network_name_str Repositorio Universidad de Cartagena
repository_id_str
dc.title.spa.fl_str_mv Osteopontina, una proteína involucrada en la progresión tumoral, y su participación en el desarrollo del carcinoma colorrectal.
dc.title.translated.eng.fl_str_mv Osteopontin, a protein involved in tumor progression, and its participation in the development of colorectal carcinoma.
title Osteopontina, una proteína involucrada en la progresión tumoral, y su participación en el desarrollo del carcinoma colorrectal.
spellingShingle Osteopontina, una proteína involucrada en la progresión tumoral, y su participación en el desarrollo del carcinoma colorrectal.
Osteopontin
Colorectal neoplasms
Immunohistochemistry
Osteopontina
Neoplasias colorrectales
Inmunohistoquímica
title_short Osteopontina, una proteína involucrada en la progresión tumoral, y su participación en el desarrollo del carcinoma colorrectal.
title_full Osteopontina, una proteína involucrada en la progresión tumoral, y su participación en el desarrollo del carcinoma colorrectal.
title_fullStr Osteopontina, una proteína involucrada en la progresión tumoral, y su participación en el desarrollo del carcinoma colorrectal.
title_full_unstemmed Osteopontina, una proteína involucrada en la progresión tumoral, y su participación en el desarrollo del carcinoma colorrectal.
title_sort Osteopontina, una proteína involucrada en la progresión tumoral, y su participación en el desarrollo del carcinoma colorrectal.
dc.creator.fl_str_mv Becerra, Daniel
Benedetti, Ines
dc.contributor.author.spa.fl_str_mv Becerra, Daniel
Benedetti, Ines
dc.subject.eng.fl_str_mv Osteopontin
Colorectal neoplasms
Immunohistochemistry
topic Osteopontin
Colorectal neoplasms
Immunohistochemistry
Osteopontina
Neoplasias colorrectales
Inmunohistoquímica
dc.subject.spa.fl_str_mv Osteopontina
Neoplasias colorrectales
Inmunohistoquímica
publishDate 2019
dc.date.accessioned.none.fl_str_mv 2019-01-15 00:00:00
dc.date.available.none.fl_str_mv 2019-01-15 00:00:00
dc.date.issued.none.fl_str_mv 2019-01-15
dc.type.spa.fl_str_mv Artículo de revista
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.version.spa.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.coarversion.spa.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.spa.fl_str_mv http://purl.org/coar/resource_type/c_6501
dc.type.content.spa.fl_str_mv Text
dc.type.driver.spa.fl_str_mv info:eu-repo/semantics/article
dc.type.local.eng.fl_str_mv Journal article
format http://purl.org/coar/resource_type/c_6501
status_str publishedVersion
dc.identifier.issn.none.fl_str_mv 2215-7840
dc.identifier.doi.none.fl_str_mv 10.32997/rcb-2018-2711
dc.identifier.eissn.none.fl_str_mv 2389-7252
dc.identifier.url.none.fl_str_mv https://doi.org/10.32997/rcb-2018-2711
identifier_str_mv 2215-7840
10.32997/rcb-2018-2711
2389-7252
url https://doi.org/10.32997/rcb-2018-2711
dc.language.iso.spa.fl_str_mv spa
language spa
dc.relation.ispartofjournal.spa.fl_str_mv Revista Ciencias Biomédicas
dc.relation.bitstream.none.fl_str_mv https://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/download/2711/2267
dc.relation.citationedition.spa.fl_str_mv Núm. 1 , Año 2019
dc.relation.citationendpage.none.fl_str_mv 21
dc.relation.citationissue.spa.fl_str_mv 1
dc.relation.citationstartpage.none.fl_str_mv 15
dc.relation.citationvolume.spa.fl_str_mv 8
dc.relation.references.spa.fl_str_mv Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136(5): E359-86. https://doi.org/10.1002/ijc.29210
WHO. Globocan 2012 - Home [Internet]. Globocan. 2012 [cited 2018 Jan 10]. Available from: http://globocan.iarc.fr/Default.aspx
McKee MD, Pedraza CE, Kaartinen MT. Osteopontin and wound healing in bone. In: Cells Tissues Organs. 2011. p. 313-9. https://doi.org/10.1159/000324244
Castello LM, Raineri D, Salmi L, Clemente N, Vaschetto R, Quaglia M, et al. Osteopontin at the Crossroads of Inflammation and Tumor Progression. Vol. 2017, Mediators of Inflammation. 2017. https://doi.org/10.1155/2017/4049098
Vaschetto R, Nicola S, Olivieri C, Boggio E, Piccolella F, Mesturini R, et al. Serum levels of osteopontin are increased in SIRS and sepsis. Intensive Care Med. 2008;34(12):2176-84. https://doi.org/10.1007/s00134-008-1268-4
Clemente N, Raineri D, Cappellano G, Boggio E, Favero F, Soluri MF, et al. Osteopontin Bridging Innate and Adaptive Immunity in Autoimmune Diseases. Vol. 2016, Journal of Immunology Research. 2016. https://doi.org/10.1155/2016/7675437
Anborgh PH, Mutrie JC, Tuck AB, Chambers AF. Role of the metastasis-promoting protein osteopontin in the tumour microenvironment. J Cell Mol Med. 2010;14(8):2037-44. https://doi.org/10.1111/j.1582-4934.2010.01115.x
Zhang J, Takahashi K, Takahashi F, Shimizu K, Ohshita F, Kameda Y, et al. Differential osteopontin expression in lung cancer. Cancer Lett. 2001; 171(2): 215-22. https://doi.org/10.1016/S0304-3835(01)00607-3
Bramwell VHC, Tuck AB, Chapman J-AW, Anborgh PH, Postenka CO, Al-Katib W, et al. Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial. Breast Cancer Res. 2014;16(1):R8. https://doi.org/10.1186/bcr3600
Kim JY, Bae B-N, Kim KS, Shin E, Park K. Osteopontin, CD44, and NFkappaB expression in gastric adenocarcinoma. Cancer Res Treat. 2009;41(1):29-35. https://doi.org/10.4143/crt.2009.41.1.29
Shang S, Plymoth A, Ge S, Feng Z, Rosen HR, Sangrajrang S, et al. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology. 2012;55(2):483-90. https://doi.org/10.1002/hep.24703
Likui W, Hong W, Shuwen Z. Clinical Significance of the Upregulated Osteopontin mRNA Expression in Human Colorectal Cancer. J Gastrointest Surg. 2010; 14:74. https://doi.org/10.1007/s11605-009-1035-z
Brenner H, Kloor M, Pox CP. Colorectal cancer. In: The Lancet. 2014. p. 1490-502. https://doi.org/10.1016/S0140-6736(13)61649-9
Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 2009; 22(4): 191-7. https://doi.org/10.1055/s-0029-1242458
Siegel R, Miller KD, Ahmedin J. Cáncer Statistics. Ca Cáncer J. 2017; 67(1): 7-30. https://doi.org/10.3322/caac.21387
Fondo Colombiano de Enfermedades de Alto Costo Cuenta de Alto Costo [CAC]. Situación del cáncer en la población adulta atendida en el sgsss de Colombia 2016. 2017.
J C-C, Ministerio de Salud y Protección Social, Sistema General de Seguridad Social en Salud - Colombia, Instituto Nacional de Cancerología, Ministerio de Salud y Protección Social. Guía de práctica clínica (GPC) para la detección temprana, diagnóstico, tratamiento, seguimiento y rehabilitación de pacientes con diagnóstico de cáncer de colon y recto. Instituto Nacional de Cancerología INC - ESE, COLCIENCIAS, Ministerio de Salud y Protección Social. 2013. 48 p.
Xue L, Williamson A, Gaines S, Andolfi C, Paul-Olson T, Neerukonda A, et al. An Update on Colorectal Cancer. Curr Probl Surg. 2018 Mar; 55(3): 76-116. https://doi.org/10.1067/j.cpsurg.2018.02.003
Bienz M, Clevers H. Linking Colorectal Cancer to Wnt Signaling. Cell. 2000 Oct; 103(2): 311-20. https://doi.org/10.1016/S0092-8674(00)00122-7
Kodach LL, Wiercinska E, de Miranda NFCC, Bleuming SA, Musler AR, Peppelenbosch MP, et al. The Bone Morphogenetic Protein Pathway Is Inactivated in the Majority of Sporadic Colorectal Cancers. Gastroenterology. 2008 May; 134(5): 1332-1341.e3. https://doi.org/10.1053/j.gastro.2008.02.059
Mi Z, Bhattacharya SD, Kim VM, Guo H, Talbotq LJ, Kuo PC. Osteopontin promotes CCL5-mesenchymal stromal cell-mediated breast cancer metastasis. Carcinogenesis. 2011; https://doi.org/10.1093/carcin/bgr009
Inés Benedetti, Niradiz Reyes. Transición epitelial-mesenquimal en la progresión del adenocarcinoma prostático. Iatreia. 2015; 28(4): 420-33. https://doi.org/10.17533/udea.iatreia.v28n4a07
Findlay VJ, Wang C, Watson DK, Camp ER. Epithelial-to mesenchymal transition and the cancer stem cell phenotype: insights from cancer biology with therapeutic implications for colorectal cancer. Cancer Gene Ther. 2014 May 2;21 (5): 181-7. https://doi.org/10.1038/cgt.2014.15
He X, Chen Z, Jia M, Zhao X. Downregulated E-Cadherin Expression Indicates Worse Prognosis in Asian Patients with Colorectal Cancer: Evidence from Meta-Analysis. Aziz SA, editor. PLoS One. 2013 Jul 29; 8(7): e70858. https://doi.org/10.1371/journal.pone.0070858
Sears CL, Garrett WS. Microbes, Microbiota, and Colon Cancer. Cell Host Microbe. 2014 Mar; 15(3): 317-28. https://doi.org/10.1016/j.chom.2014.02.007
Tjalsma H, Boleij A, Marchesi JR, Dutilh BE. A bacterial driver-passenger model for colorectal cancer: Beyond the usual suspects. Nat Rev Microbiol. 2012. https://doi.org/10.1038/nrmicro2819
Schwabe RF, Jobin C. The microbiome and cancer. Nat Rev Cancer. 2013 Nov 17; 13(11): 800-12. https://doi.org/10.1038/nrc3610
Rubinstein MR, Wang X, Liu W, Hao Y, Cai G, Han YW. Fusobacterium nucleatum Promotes Colorectal Carcinogenesis by Modulating E-Cadherin/β-Catenin Signaling via its FadA Adhesin. Cell Host Microbe. 2013; https://doi.org/10.1016/j.chom.2013.07.012
Kostic AD, Chun E, Robertson L, Glickman JN, Gallini CA, Michaud M, et al. Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment. Cell Host Microbe. 2013 Aug; 14(2): 207-15. https://doi.org/10.1016/j.chom.2013.07.007
Boleij A, Van Gelder MMHJ, Swinkels DW, Tjalsma H. Clinical importance of streptococcus gallolyticus infection among colorectal cancer patients: Systematic review and meta-analysis. Clin Infect Dis. 2011. https://doi.org/10.1093/cid/cir609
Shiryaev SA, Remacle AG, Chernov A V., Golubkov VS, Motamedchaboki K, Muranaka N, et al. Substrate cleavage profiling suggests a distinct function of bacteroides fragilis metalloproteinases (fragilysin and metalloproteinase ii) at the microbiome-inflammation-cancer interface. J Biol Chem. 2013. https://doi.org/10.1074/jbc.M113.516153
Yang Y, Wang X, Huycke T, Moore DR, Lightfoot SA, Huycke MM. Colon Macrophages Polarized by Commensal Bacteria Cause Colitis and Cancer through the Bystander Effect. Transl Oncol. 2013 Oct; 6(5): 596-IN8. https://doi.org/10.1593/tlo.13412
Denhardt DT, Noda M. Osteopontin expression and function: role in bone remodeling. Vols. 30-31, Journal of cellular biochemistry. Supplement. 1998. p. 92-102. https://doi.org/10.1002/(SICI)1097-4644(1998)72:30/31+<92::AID-JCB13>3.0.CO;2-A
Denhardt DT, Guo X. Osteopontin: a protein with diverse functions. FASEB J. 1993; 7: 1475-82. https://doi.org/10.1096/fasebj.7.15.8262332
Huang R, Quan Y, Chen J, Wang T, Xu M, Ye M, et al. Osteopontin Promotes Cell Migration and Invasion, and Inhibits Apoptosis and Autophagy in Colorectal Cancer by activating the p38 MAPK Signaling Pathway. Cell Physiol Biochem. 2017; 200032:1851-64. https://doi.org/10.1159/000471933
Thorsen SB, Lundberg M, Villablanca A, Christensen SLT, Belling KC, Nielsen BS, et al. Detection of serological biomarkers by proximity extension assay for detection of colorectal neoplasias in symptomatic individuals. J Transl Med. 2013;11(1). https://doi.org/10.1186/1479-5876-11-253
Kahles F, Findeisen HM, Bruemmer D. Osteopontin: A novel regulator at the cross roads of inflammation, obesity and diabetes. Vol. 3, Molecular Metabolism. 2014. p. 384-93. https://doi.org/10.1016/j.molmet.2014.03.004
Lund SA, Wilson CL, Raines EW, Tang J, Giachelli CM, Scatena M. Osteopontin mediates macrophage chemotaxis via ??4 and ??9 integrins and survival via the ??4 integrin. J Cell Biochem. 2013; 114(5): 1194-202. https://doi.org/10.1002/jcb.24462
O'Regan AW, Hayden JM, Berman JS. Osteopontin augments CD3-mediated interferon-gamma and CD40 ligand expression by T cells, which results in IL-12 production from peripheral blood mononuclear cells. Vol. 68, J Leukoc Biol. 2000. p. 495-502.
Liaw L, Birk DE, Ballas CB, Whitsitt JS, Davidson JM, Hogan BL, et al. Altered wound healing in mice lacking a functional osteopontin gene (spp1). J Clin Invest. 2007; 101(7): 1468-78. https://doi.org/10.1172/JCI2131
Mori R, Shaw TJ, Martin P. Molecular mechanisms linking wound inflammation and fibrosis: knockdown of osteopontin leads to rapid repair and reduced scarring. J Exp Med. 2008 Jan 21; 205(1): 43-51. https://doi.org/10.1084/jem.20071412
Higashiyama M, Ito T, Tanaka E, Shimada Y. Prognostic significance of osteopontin expression in human gastric carcinoma. Ann Surg Oncol. 2007; 14(12): 3419-27. https://doi.org/10.1245/s10434-007-9564-8
Weber GF, Lett GS, Haubein NC. Osteopontin is a marker for cancer aggressiveness and patient survival. Br J Cancer. 2010; 103(6): 861-9. https://doi.org/10.1038/sj.bjc.6605834
Zhang H, Li L, Dong Q, Wang Y, Feng Q, Ou X, et al. Activation of PKA/ CREB Signaling is Involved in BMP9-Induced Osteogenic Differentiation of Mesenchymal Stem Cells. Cell Physiol Biochem. 2015; 37(2): 548-62. https://doi.org/10.1159/000430376
Rangaswami H, Bulbule A, Kundu GC. Osteopontin: Role in cell signaling and cancer progression. Vol. 16, Trends in Cell Biology. 2006. p. 79-87. https://doi.org/10.1016/j.tcb.2005.12.005
Hirama M, Takahashi F, Takahashi K, Akutagawa S, Shimizu K, Soma S, et al. Osteopontin overproduced by tumor cells acts as a potent angiogenic factor contributing to tumor growth. Cancer Lett. 2003; 198(1): 107-17. https://doi.org/10.1016/S0304-3835(03)00286-6
Weber GF. Molecular mechanisms of metastasis. Vol. 270, Cancer Letters. 2008. p. 181-90. https://doi.org/10.1016/j.canlet.2008.04.030
Atai NA, Bansal M, Lo C, Bosman J, Tigchelaar W, Bosch KS, et al. Osteopontin is up-regulated and associated with neutrophil and macrophage infiltration in glioblastoma. Immunology. 2011. https://doi.org/10.1111/j.1365-2567.2010.03335.x
Dai J, Li B, Shi J, Peng L, Zhang D, Qian W, et al. A humanized anti-osteopontin antibody inhibits breast cancer growth and metastasis in vivo. Cancer Immunol Immunother. 2010 Mar 19; 59(3): 355-66. https://doi.org/10.1007/s00262-009-0754-z
Weber GF, Lett GS, Haubein NC. Categorical meta-analysis of osteopontin as a clinical cancer marker. Oncol Rep. 2011. https://doi.org/10.3892/or.2010.1106
Castellano G, Malaponte G, Mazzarino MC, Figini M, Marchese F, Gangemi P, et al. Activation of the osteopontin/matrix metalloproteinase-9 pathway correlates with prostate cancer progression. Clin Cancer Res. 2008. https://doi.org/10.1158/1078-0432.CCR-08-0870
Thoms JW, Dal Pra A, Anborgh PH, Christensen E, Fleshner N, Menard C, et al. Plasma osteopontin as a biomarker of prostate cancer aggression: Relationship to risk category and treatment response. Br J Cancer. 2012; 107(5): 840-6. https://doi.org/10.1038/bjc.2012.345
Trotter TN, Yang Y. Matricellular proteins as regulators of cancer metastasis to bone. Matrix Biol. 2016 May; 52-54(2): 301-14. https://doi.org/10.1016/j.matbio.2016.01.006
Bramwell VHC, Doig GS, Tuck AB, Wilson SM, Tonkin KS, Tomiak A, et al. Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin Cancer Res. 2006. https://doi.org/10.1158/1078-0432.CCR-05-2354
Li NY, Weber CE, Mi Z, Wai PY, Cuevas BD, Kuo PC. Osteopontin up-regulatescritical epithelial-mesenchymal transition transcription factors to induce an aggressive breast cancer phenotype. In: Journal of the American College of Surgeons. 2013. https://doi.org/10.1016/j.jamcollsurg.2013.02.025
Wang XM, Li J, Yan MX, Liu L, Jia DS, Geng Q, et al. Integrative Analyses Identify Osteopontin, LAMB3 and ITGB1 as Critical Pro-Metastatic Genes for Lung Cancer. PLoS One. 2013. https://doi.org/10.1371/journal.pone.0055714
Mole DJ, O'Neill C, Hamilton P, Olabi B, Robinson V, Williams L, et al. Expression of osteopontin coregulators in primary colorectal cancer and associated liver metastases. Br J Cancer. 2011. https://doi.org/10.1038/bjc.2011.33
Rud AK, Boye K, Oijordsbakken M, Lund-Iversen M, Halvorsen AR, Solberg SK, et al. Osteopontin is a prognostic biomarker in non-small cell lung cancer. BMC Cancer. 2013. https://doi.org/10.1186/1471-2407-13-540
Li Y, Li L, Wang JT, Kan X, Lu JG. Elevated content of osteopontin in plasma and tumor tissues of patients with laryngeal and hypopharyngeal carcinoma associated with metastasis and prognosis. Med Oncol. 2012. https://doi.org/10.1007/s12032-011-0012-z
Chang P-L, Harkins L, Hsieh Y-H, Hicks P, Sappayatosok K, Yodsanga S, et al. Osteopontin expression in normal skin and non-melanoma skin tumors. J Histochem Cytochem. 2008. https://doi.org/10.1369/jhc.7A7325.2007
Kale S, Raja R, Thorat D, Soundararajan G, Patil T V., Kundu GC. Osteopontin signaling upregulates cyclooxygenase-2 expression in tumor-associated macrophages leading to enhanced angiogenesis and melanoma growth via α9β1 integrin. Oncogene. 2014. https://doi.org/10.1038/onc.2013.184
Wei R, Pik J, Wong C, Kwok HF. Osteopontin -- a promising biomarker for cancer therapy. 2017;8. https://doi.org/10.7150/jca.20480
Subramani V, Thiyagarajan M, Malathi N, Rajan ST. OPN - Revisited. Journal of Clinical and Diagnostic Research. 2015. https://doi.org/10.7860/JCDR/2015/12872.6111
Ng L, Wan T, Chow A, Iyer D, Man J, Chen G, et al. Osteopontin Overexpression Induced Tumor Progression and Chemoresistance to Oxaliplatin through Induction of Stem-Like Properties in Human Colorectal Cancer. Stem Cells Int. 2015. https://doi.org/10.1155/2015/247892
Eschrich S, Yang I, Bloom G, Kwong KY, Boulware D, Cantor A, et al. Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol. 2005. https://doi.org/10.1200/JCO.2005.00.695
Leslie A, Carey FA, Pratt NR, Steele RJC. The colorectal adenoma-carcinoma sequence. Vol. 89, British Journal of Surgery. 2002. p. 845-60. https://doi.org/10.1046/j.1365-2168.2002.02120.x
Paoni NF, Feldman MW, Gutierrez LS, Ploplis V a, Castellino FJ. Transcriptional profiling of the transition from normal intestinal epithelia to adenomas and carcinomas in the APCMin/ + mouse. Physiol Genomics. 2003; 15(3): 228-35. https://doi.org/10.1152/physiolgenomics.00078.2003
Chambers AF, Behrend EI, Wilson SM, Denhardt DT. Induction of expression of osteopontin (OPN; secreted phosphoprotein) in metastatic, ras-transformed NIH 3T3 cells. Anticancer Res. 1992; 12(1): 43-7.
Li J, Yang GZ, Zhu ZM, Zhou ZY, Li L. Osteopontin is overexpressed in colorectal carcinoma and is correlated with P53 by immunohistochemistry. Exp Ther Med. 2012;3(4):621-4. https://doi.org/10.3892/etm.2012.465
Valcz G, Sipos F, Krenács T, Molnár J, Patai Á V., Leiszter K, et al. Elevated osteopontin expression and proliferative/apoptotic ratio in the colorectal adenoma-dysplasia-carcinoma sequence. Pathol Oncol Res. 2010; 16(4): 541-5. https://doi.org/10.1007/s12253-010-9260-z
Takami Y, Russell MB, Gao C, Mi Z, Guo H, Mantyh CR, et al. Sp1 regulates osteopontin expression in SW480 human colon adenocarcinoma cells. Surgery. 2007; 142(2): 163-9. https://doi.org/10.1016/j.surg.2007.02.015
Martinez C, Churchman M, Freeman T, Ilyas M. Osteopontin provides early proliferative drive and may be dependent upon aberrant c-myc signalling in murine intestinal tumours. Exp Mol Pathol. 2010; 88(2): 272-7. https://doi.org/10.1016/j.yexmp.2009.12.008
Liu Y-N, Kang B-B, Chen JH. Transcriptional regulation of human osteopontin promoter by C/EBPalpha and AML-1 in metastatic cancer cells. Oncogene. 2004;23(1):278-88. https://doi.org/10.1038/sj.onc.1207022
Zagani R, Hamzaoui N, Cacheux W, de Reyniès A, Terris B, Chaussade S, et al. Cyclooxygenase-2 Inhibitors Down-regulate Osteopontin and Nr4a2-New Therapeutic Targets for Colorectal Cancers. Gastroenterology. 2009;137(4). https://doi.org/10.1053/j.gastro.2009.06.039
El-Tanani M, Platt-Higgins A, Rudland PS, Campbell FC. Ets gene PEA3 cooperates with ??-catenin-Lef-1 and c-Jun in regulation of osteopontin transcription. J Biol Chem. 2004; 279(20): 20794-806. https://doi.org/10.1074/jbc.M311131200
Rohde F, Rimkus C, Friederichs J, Rosenberg R, Marthen C, Doll D, et al. Expression of osteopontin, a target gene of de-regulated Wnt signaling, predicts survival in colon cancer. Int J Cancer. 2007; 121(8): 1717-23. https://doi.org/10.1002/ijc.22868
El-Tanani MK, Jin D, Campbell FC, Johnston PG. Interferon-induced transmembrane 3 binds osteopontin in vitro: Expressed in vivo IFITM3 reduced OPN expression. Oncogene. 2010. https://doi.org/10.1038/onc.2009.379
Wild N, Andres H, Rollinger W, Krause F, Dilba P, Tacke M, et al. A combination of serum markers for the early detection of colorectal cancer. Clin Cancer Res. 2010; 16(24): 6111-21. https://doi.org/10.1158/1078-0432.CCR-10-0119
Ng L, Wan TMH, Lam CSC, Chow AKM, Wong SKM, Man JHW, et al. Post-operative plasma osteopontin predicts distant metastasis in human colorectal cancer. PLoS One. 2015; 10(5). https://doi.org/10.1371/journal.pone.0126219
Zhao M, Liang F, Zhang B, Yan W, Zhang J. The impact of osteopontin on prognosis and clinicopathology of colorectal cancer patients: A systematic meta-analysis. Sci Rep. 2015; 5. https://doi.org/10.1038/srep12713
Likui W, Hong W, Shuwen Z, Yuangang Y, Yan W. The Potential of Osteopontin as a Therapeutic Target for Human Colorectal Cancer. J Gastrointest Surg. 2011 Apr 12;15(4):652-9. https://doi.org/10.1007/s11605-011-1445-6
Boudjadi S, Bernatchez G, Beaulieu JF, Carrier JC. Control of the human osteopontin promoter by ERRα in colorectal cancer. Am J Pathol. 2013; 183(1): 266-76. https://doi.org/10.1016/j.ajpath.2013.03.021
Youssef NS, Osman WM. Relationship between osteopontin and β-catenin immunohistochemical expression and prognostic parameters of colorectal carcinoma. Int J Clin Exp Pathol. 2015; 8(2): 1503-14.
dc.rights.spa.fl_str_mv Revista Ciencias Biomédicas - 2018
dc.rights.uri.spa.fl_str_mv https://creativecommons.org/licenses/by-nc-sa/4.0
dc.rights.coar.spa.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.rights.accessrights.spa.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv Revista Ciencias Biomédicas - 2018
https://creativecommons.org/licenses/by-nc-sa/4.0
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.mimetype.spa.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv Universidad de Cartagena
dc.source.spa.fl_str_mv https://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/view/2711
institution Universidad de Cartagena
bitstream.url.fl_str_mv https://repositorio.unicartagena.edu.co/bitstreams/3da2383d-7096-4acd-a5f6-74d5d0f80727/download
bitstream.checksum.fl_str_mv 17d8e66a148790fc683d5eabd5b3a347
bitstream.checksumAlgorithm.fl_str_mv MD5
repository.name.fl_str_mv Biblioteca Digital Universidad de Cartagena
repository.mail.fl_str_mv bdigital@metabiblioteca.com
_version_ 1818153223054163968
spelling Becerra, DanielBenedetti, Ines2019-01-15 00:00:002019-01-15 00:00:002019-01-152215-784010.32997/rcb-2018-27112389-7252https://doi.org/10.32997/rcb-2018-2711application/pdfspaUniversidad de CartagenaRevista Ciencias Biomédicashttps://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/download/2711/2267Núm. 1 , Año 2019211158Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136(5): E359-86. https://doi.org/10.1002/ijc.29210WHO. Globocan 2012 - Home [Internet]. Globocan. 2012 [cited 2018 Jan 10]. Available from: http://globocan.iarc.fr/Default.aspxMcKee MD, Pedraza CE, Kaartinen MT. Osteopontin and wound healing in bone. In: Cells Tissues Organs. 2011. p. 313-9. https://doi.org/10.1159/000324244Castello LM, Raineri D, Salmi L, Clemente N, Vaschetto R, Quaglia M, et al. Osteopontin at the Crossroads of Inflammation and Tumor Progression. Vol. 2017, Mediators of Inflammation. 2017. https://doi.org/10.1155/2017/4049098Vaschetto R, Nicola S, Olivieri C, Boggio E, Piccolella F, Mesturini R, et al. Serum levels of osteopontin are increased in SIRS and sepsis. Intensive Care Med. 2008;34(12):2176-84. https://doi.org/10.1007/s00134-008-1268-4Clemente N, Raineri D, Cappellano G, Boggio E, Favero F, Soluri MF, et al. Osteopontin Bridging Innate and Adaptive Immunity in Autoimmune Diseases. Vol. 2016, Journal of Immunology Research. 2016. https://doi.org/10.1155/2016/7675437Anborgh PH, Mutrie JC, Tuck AB, Chambers AF. Role of the metastasis-promoting protein osteopontin in the tumour microenvironment. J Cell Mol Med. 2010;14(8):2037-44. https://doi.org/10.1111/j.1582-4934.2010.01115.xZhang J, Takahashi K, Takahashi F, Shimizu K, Ohshita F, Kameda Y, et al. Differential osteopontin expression in lung cancer. Cancer Lett. 2001; 171(2): 215-22. https://doi.org/10.1016/S0304-3835(01)00607-3Bramwell VHC, Tuck AB, Chapman J-AW, Anborgh PH, Postenka CO, Al-Katib W, et al. Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial. Breast Cancer Res. 2014;16(1):R8. https://doi.org/10.1186/bcr3600Kim JY, Bae B-N, Kim KS, Shin E, Park K. Osteopontin, CD44, and NFkappaB expression in gastric adenocarcinoma. Cancer Res Treat. 2009;41(1):29-35. https://doi.org/10.4143/crt.2009.41.1.29Shang S, Plymoth A, Ge S, Feng Z, Rosen HR, Sangrajrang S, et al. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology. 2012;55(2):483-90. https://doi.org/10.1002/hep.24703Likui W, Hong W, Shuwen Z. Clinical Significance of the Upregulated Osteopontin mRNA Expression in Human Colorectal Cancer. J Gastrointest Surg. 2010; 14:74. https://doi.org/10.1007/s11605-009-1035-zBrenner H, Kloor M, Pox CP. Colorectal cancer. In: The Lancet. 2014. p. 1490-502. https://doi.org/10.1016/S0140-6736(13)61649-9Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 2009; 22(4): 191-7. https://doi.org/10.1055/s-0029-1242458Siegel R, Miller KD, Ahmedin J. Cáncer Statistics. Ca Cáncer J. 2017; 67(1): 7-30. https://doi.org/10.3322/caac.21387Fondo Colombiano de Enfermedades de Alto Costo Cuenta de Alto Costo [CAC]. Situación del cáncer en la población adulta atendida en el sgsss de Colombia 2016. 2017.J C-C, Ministerio de Salud y Protección Social, Sistema General de Seguridad Social en Salud - Colombia, Instituto Nacional de Cancerología, Ministerio de Salud y Protección Social. Guía de práctica clínica (GPC) para la detección temprana, diagnóstico, tratamiento, seguimiento y rehabilitación de pacientes con diagnóstico de cáncer de colon y recto. Instituto Nacional de Cancerología INC - ESE, COLCIENCIAS, Ministerio de Salud y Protección Social. 2013. 48 p.Xue L, Williamson A, Gaines S, Andolfi C, Paul-Olson T, Neerukonda A, et al. An Update on Colorectal Cancer. Curr Probl Surg. 2018 Mar; 55(3): 76-116. https://doi.org/10.1067/j.cpsurg.2018.02.003Bienz M, Clevers H. Linking Colorectal Cancer to Wnt Signaling. Cell. 2000 Oct; 103(2): 311-20. https://doi.org/10.1016/S0092-8674(00)00122-7Kodach LL, Wiercinska E, de Miranda NFCC, Bleuming SA, Musler AR, Peppelenbosch MP, et al. The Bone Morphogenetic Protein Pathway Is Inactivated in the Majority of Sporadic Colorectal Cancers. Gastroenterology. 2008 May; 134(5): 1332-1341.e3. https://doi.org/10.1053/j.gastro.2008.02.059Mi Z, Bhattacharya SD, Kim VM, Guo H, Talbotq LJ, Kuo PC. Osteopontin promotes CCL5-mesenchymal stromal cell-mediated breast cancer metastasis. Carcinogenesis. 2011; https://doi.org/10.1093/carcin/bgr009Inés Benedetti, Niradiz Reyes. Transición epitelial-mesenquimal en la progresión del adenocarcinoma prostático. Iatreia. 2015; 28(4): 420-33. https://doi.org/10.17533/udea.iatreia.v28n4a07Findlay VJ, Wang C, Watson DK, Camp ER. Epithelial-to mesenchymal transition and the cancer stem cell phenotype: insights from cancer biology with therapeutic implications for colorectal cancer. Cancer Gene Ther. 2014 May 2;21 (5): 181-7. https://doi.org/10.1038/cgt.2014.15He X, Chen Z, Jia M, Zhao X. Downregulated E-Cadherin Expression Indicates Worse Prognosis in Asian Patients with Colorectal Cancer: Evidence from Meta-Analysis. Aziz SA, editor. PLoS One. 2013 Jul 29; 8(7): e70858. https://doi.org/10.1371/journal.pone.0070858Sears CL, Garrett WS. Microbes, Microbiota, and Colon Cancer. Cell Host Microbe. 2014 Mar; 15(3): 317-28. https://doi.org/10.1016/j.chom.2014.02.007Tjalsma H, Boleij A, Marchesi JR, Dutilh BE. A bacterial driver-passenger model for colorectal cancer: Beyond the usual suspects. Nat Rev Microbiol. 2012. https://doi.org/10.1038/nrmicro2819Schwabe RF, Jobin C. The microbiome and cancer. Nat Rev Cancer. 2013 Nov 17; 13(11): 800-12. https://doi.org/10.1038/nrc3610Rubinstein MR, Wang X, Liu W, Hao Y, Cai G, Han YW. Fusobacterium nucleatum Promotes Colorectal Carcinogenesis by Modulating E-Cadherin/β-Catenin Signaling via its FadA Adhesin. Cell Host Microbe. 2013; https://doi.org/10.1016/j.chom.2013.07.012Kostic AD, Chun E, Robertson L, Glickman JN, Gallini CA, Michaud M, et al. Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment. Cell Host Microbe. 2013 Aug; 14(2): 207-15. https://doi.org/10.1016/j.chom.2013.07.007Boleij A, Van Gelder MMHJ, Swinkels DW, Tjalsma H. Clinical importance of streptococcus gallolyticus infection among colorectal cancer patients: Systematic review and meta-analysis. Clin Infect Dis. 2011. https://doi.org/10.1093/cid/cir609Shiryaev SA, Remacle AG, Chernov A V., Golubkov VS, Motamedchaboki K, Muranaka N, et al. Substrate cleavage profiling suggests a distinct function of bacteroides fragilis metalloproteinases (fragilysin and metalloproteinase ii) at the microbiome-inflammation-cancer interface. J Biol Chem. 2013. https://doi.org/10.1074/jbc.M113.516153Yang Y, Wang X, Huycke T, Moore DR, Lightfoot SA, Huycke MM. Colon Macrophages Polarized by Commensal Bacteria Cause Colitis and Cancer through the Bystander Effect. Transl Oncol. 2013 Oct; 6(5): 596-IN8. https://doi.org/10.1593/tlo.13412Denhardt DT, Noda M. Osteopontin expression and function: role in bone remodeling. Vols. 30-31, Journal of cellular biochemistry. Supplement. 1998. p. 92-102. https://doi.org/10.1002/(SICI)1097-4644(1998)72:30/31+<92::AID-JCB13>3.0.CO;2-ADenhardt DT, Guo X. Osteopontin: a protein with diverse functions. FASEB J. 1993; 7: 1475-82. https://doi.org/10.1096/fasebj.7.15.8262332Huang R, Quan Y, Chen J, Wang T, Xu M, Ye M, et al. Osteopontin Promotes Cell Migration and Invasion, and Inhibits Apoptosis and Autophagy in Colorectal Cancer by activating the p38 MAPK Signaling Pathway. Cell Physiol Biochem. 2017; 200032:1851-64. https://doi.org/10.1159/000471933Thorsen SB, Lundberg M, Villablanca A, Christensen SLT, Belling KC, Nielsen BS, et al. Detection of serological biomarkers by proximity extension assay for detection of colorectal neoplasias in symptomatic individuals. J Transl Med. 2013;11(1). https://doi.org/10.1186/1479-5876-11-253Kahles F, Findeisen HM, Bruemmer D. Osteopontin: A novel regulator at the cross roads of inflammation, obesity and diabetes. Vol. 3, Molecular Metabolism. 2014. p. 384-93. https://doi.org/10.1016/j.molmet.2014.03.004Lund SA, Wilson CL, Raines EW, Tang J, Giachelli CM, Scatena M. Osteopontin mediates macrophage chemotaxis via ??4 and ??9 integrins and survival via the ??4 integrin. J Cell Biochem. 2013; 114(5): 1194-202. https://doi.org/10.1002/jcb.24462O'Regan AW, Hayden JM, Berman JS. Osteopontin augments CD3-mediated interferon-gamma and CD40 ligand expression by T cells, which results in IL-12 production from peripheral blood mononuclear cells. Vol. 68, J Leukoc Biol. 2000. p. 495-502.Liaw L, Birk DE, Ballas CB, Whitsitt JS, Davidson JM, Hogan BL, et al. Altered wound healing in mice lacking a functional osteopontin gene (spp1). J Clin Invest. 2007; 101(7): 1468-78. https://doi.org/10.1172/JCI2131Mori R, Shaw TJ, Martin P. Molecular mechanisms linking wound inflammation and fibrosis: knockdown of osteopontin leads to rapid repair and reduced scarring. J Exp Med. 2008 Jan 21; 205(1): 43-51. https://doi.org/10.1084/jem.20071412Higashiyama M, Ito T, Tanaka E, Shimada Y. Prognostic significance of osteopontin expression in human gastric carcinoma. Ann Surg Oncol. 2007; 14(12): 3419-27. https://doi.org/10.1245/s10434-007-9564-8Weber GF, Lett GS, Haubein NC. Osteopontin is a marker for cancer aggressiveness and patient survival. Br J Cancer. 2010; 103(6): 861-9. https://doi.org/10.1038/sj.bjc.6605834Zhang H, Li L, Dong Q, Wang Y, Feng Q, Ou X, et al. Activation of PKA/ CREB Signaling is Involved in BMP9-Induced Osteogenic Differentiation of Mesenchymal Stem Cells. Cell Physiol Biochem. 2015; 37(2): 548-62. https://doi.org/10.1159/000430376Rangaswami H, Bulbule A, Kundu GC. Osteopontin: Role in cell signaling and cancer progression. Vol. 16, Trends in Cell Biology. 2006. p. 79-87. https://doi.org/10.1016/j.tcb.2005.12.005Hirama M, Takahashi F, Takahashi K, Akutagawa S, Shimizu K, Soma S, et al. Osteopontin overproduced by tumor cells acts as a potent angiogenic factor contributing to tumor growth. Cancer Lett. 2003; 198(1): 107-17. https://doi.org/10.1016/S0304-3835(03)00286-6Weber GF. Molecular mechanisms of metastasis. Vol. 270, Cancer Letters. 2008. p. 181-90. https://doi.org/10.1016/j.canlet.2008.04.030Atai NA, Bansal M, Lo C, Bosman J, Tigchelaar W, Bosch KS, et al. Osteopontin is up-regulated and associated with neutrophil and macrophage infiltration in glioblastoma. Immunology. 2011. https://doi.org/10.1111/j.1365-2567.2010.03335.xDai J, Li B, Shi J, Peng L, Zhang D, Qian W, et al. A humanized anti-osteopontin antibody inhibits breast cancer growth and metastasis in vivo. Cancer Immunol Immunother. 2010 Mar 19; 59(3): 355-66. https://doi.org/10.1007/s00262-009-0754-zWeber GF, Lett GS, Haubein NC. Categorical meta-analysis of osteopontin as a clinical cancer marker. Oncol Rep. 2011. https://doi.org/10.3892/or.2010.1106Castellano G, Malaponte G, Mazzarino MC, Figini M, Marchese F, Gangemi P, et al. Activation of the osteopontin/matrix metalloproteinase-9 pathway correlates with prostate cancer progression. Clin Cancer Res. 2008. https://doi.org/10.1158/1078-0432.CCR-08-0870Thoms JW, Dal Pra A, Anborgh PH, Christensen E, Fleshner N, Menard C, et al. Plasma osteopontin as a biomarker of prostate cancer aggression: Relationship to risk category and treatment response. Br J Cancer. 2012; 107(5): 840-6. https://doi.org/10.1038/bjc.2012.345Trotter TN, Yang Y. Matricellular proteins as regulators of cancer metastasis to bone. Matrix Biol. 2016 May; 52-54(2): 301-14. https://doi.org/10.1016/j.matbio.2016.01.006Bramwell VHC, Doig GS, Tuck AB, Wilson SM, Tonkin KS, Tomiak A, et al. Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin Cancer Res. 2006. https://doi.org/10.1158/1078-0432.CCR-05-2354Li NY, Weber CE, Mi Z, Wai PY, Cuevas BD, Kuo PC. Osteopontin up-regulatescritical epithelial-mesenchymal transition transcription factors to induce an aggressive breast cancer phenotype. In: Journal of the American College of Surgeons. 2013. https://doi.org/10.1016/j.jamcollsurg.2013.02.025Wang XM, Li J, Yan MX, Liu L, Jia DS, Geng Q, et al. Integrative Analyses Identify Osteopontin, LAMB3 and ITGB1 as Critical Pro-Metastatic Genes for Lung Cancer. PLoS One. 2013. https://doi.org/10.1371/journal.pone.0055714Mole DJ, O'Neill C, Hamilton P, Olabi B, Robinson V, Williams L, et al. Expression of osteopontin coregulators in primary colorectal cancer and associated liver metastases. Br J Cancer. 2011. https://doi.org/10.1038/bjc.2011.33Rud AK, Boye K, Oijordsbakken M, Lund-Iversen M, Halvorsen AR, Solberg SK, et al. Osteopontin is a prognostic biomarker in non-small cell lung cancer. BMC Cancer. 2013. https://doi.org/10.1186/1471-2407-13-540Li Y, Li L, Wang JT, Kan X, Lu JG. Elevated content of osteopontin in plasma and tumor tissues of patients with laryngeal and hypopharyngeal carcinoma associated with metastasis and prognosis. Med Oncol. 2012. https://doi.org/10.1007/s12032-011-0012-zChang P-L, Harkins L, Hsieh Y-H, Hicks P, Sappayatosok K, Yodsanga S, et al. Osteopontin expression in normal skin and non-melanoma skin tumors. J Histochem Cytochem. 2008. https://doi.org/10.1369/jhc.7A7325.2007Kale S, Raja R, Thorat D, Soundararajan G, Patil T V., Kundu GC. Osteopontin signaling upregulates cyclooxygenase-2 expression in tumor-associated macrophages leading to enhanced angiogenesis and melanoma growth via α9β1 integrin. Oncogene. 2014. https://doi.org/10.1038/onc.2013.184Wei R, Pik J, Wong C, Kwok HF. Osteopontin -- a promising biomarker for cancer therapy. 2017;8. https://doi.org/10.7150/jca.20480Subramani V, Thiyagarajan M, Malathi N, Rajan ST. OPN - Revisited. Journal of Clinical and Diagnostic Research. 2015. https://doi.org/10.7860/JCDR/2015/12872.6111Ng L, Wan T, Chow A, Iyer D, Man J, Chen G, et al. Osteopontin Overexpression Induced Tumor Progression and Chemoresistance to Oxaliplatin through Induction of Stem-Like Properties in Human Colorectal Cancer. Stem Cells Int. 2015. https://doi.org/10.1155/2015/247892Eschrich S, Yang I, Bloom G, Kwong KY, Boulware D, Cantor A, et al. Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol. 2005. https://doi.org/10.1200/JCO.2005.00.695Leslie A, Carey FA, Pratt NR, Steele RJC. The colorectal adenoma-carcinoma sequence. Vol. 89, British Journal of Surgery. 2002. p. 845-60. https://doi.org/10.1046/j.1365-2168.2002.02120.xPaoni NF, Feldman MW, Gutierrez LS, Ploplis V a, Castellino FJ. Transcriptional profiling of the transition from normal intestinal epithelia to adenomas and carcinomas in the APCMin/ + mouse. Physiol Genomics. 2003; 15(3): 228-35. https://doi.org/10.1152/physiolgenomics.00078.2003Chambers AF, Behrend EI, Wilson SM, Denhardt DT. Induction of expression of osteopontin (OPN; secreted phosphoprotein) in metastatic, ras-transformed NIH 3T3 cells. Anticancer Res. 1992; 12(1): 43-7.Li J, Yang GZ, Zhu ZM, Zhou ZY, Li L. Osteopontin is overexpressed in colorectal carcinoma and is correlated with P53 by immunohistochemistry. Exp Ther Med. 2012;3(4):621-4. https://doi.org/10.3892/etm.2012.465Valcz G, Sipos F, Krenács T, Molnár J, Patai Á V., Leiszter K, et al. Elevated osteopontin expression and proliferative/apoptotic ratio in the colorectal adenoma-dysplasia-carcinoma sequence. Pathol Oncol Res. 2010; 16(4): 541-5. https://doi.org/10.1007/s12253-010-9260-zTakami Y, Russell MB, Gao C, Mi Z, Guo H, Mantyh CR, et al. Sp1 regulates osteopontin expression in SW480 human colon adenocarcinoma cells. Surgery. 2007; 142(2): 163-9. https://doi.org/10.1016/j.surg.2007.02.015Martinez C, Churchman M, Freeman T, Ilyas M. Osteopontin provides early proliferative drive and may be dependent upon aberrant c-myc signalling in murine intestinal tumours. Exp Mol Pathol. 2010; 88(2): 272-7. https://doi.org/10.1016/j.yexmp.2009.12.008Liu Y-N, Kang B-B, Chen JH. Transcriptional regulation of human osteopontin promoter by C/EBPalpha and AML-1 in metastatic cancer cells. Oncogene. 2004;23(1):278-88. https://doi.org/10.1038/sj.onc.1207022Zagani R, Hamzaoui N, Cacheux W, de Reyniès A, Terris B, Chaussade S, et al. Cyclooxygenase-2 Inhibitors Down-regulate Osteopontin and Nr4a2-New Therapeutic Targets for Colorectal Cancers. Gastroenterology. 2009;137(4). https://doi.org/10.1053/j.gastro.2009.06.039El-Tanani M, Platt-Higgins A, Rudland PS, Campbell FC. Ets gene PEA3 cooperates with ??-catenin-Lef-1 and c-Jun in regulation of osteopontin transcription. J Biol Chem. 2004; 279(20): 20794-806. https://doi.org/10.1074/jbc.M311131200Rohde F, Rimkus C, Friederichs J, Rosenberg R, Marthen C, Doll D, et al. Expression of osteopontin, a target gene of de-regulated Wnt signaling, predicts survival in colon cancer. Int J Cancer. 2007; 121(8): 1717-23. https://doi.org/10.1002/ijc.22868El-Tanani MK, Jin D, Campbell FC, Johnston PG. Interferon-induced transmembrane 3 binds osteopontin in vitro: Expressed in vivo IFITM3 reduced OPN expression. Oncogene. 2010. https://doi.org/10.1038/onc.2009.379Wild N, Andres H, Rollinger W, Krause F, Dilba P, Tacke M, et al. A combination of serum markers for the early detection of colorectal cancer. Clin Cancer Res. 2010; 16(24): 6111-21. https://doi.org/10.1158/1078-0432.CCR-10-0119Ng L, Wan TMH, Lam CSC, Chow AKM, Wong SKM, Man JHW, et al. Post-operative plasma osteopontin predicts distant metastasis in human colorectal cancer. PLoS One. 2015; 10(5). https://doi.org/10.1371/journal.pone.0126219Zhao M, Liang F, Zhang B, Yan W, Zhang J. The impact of osteopontin on prognosis and clinicopathology of colorectal cancer patients: A systematic meta-analysis. Sci Rep. 2015; 5. https://doi.org/10.1038/srep12713Likui W, Hong W, Shuwen Z, Yuangang Y, Yan W. The Potential of Osteopontin as a Therapeutic Target for Human Colorectal Cancer. J Gastrointest Surg. 2011 Apr 12;15(4):652-9. https://doi.org/10.1007/s11605-011-1445-6Boudjadi S, Bernatchez G, Beaulieu JF, Carrier JC. Control of the human osteopontin promoter by ERRα in colorectal cancer. Am J Pathol. 2013; 183(1): 266-76. https://doi.org/10.1016/j.ajpath.2013.03.021Youssef NS, Osman WM. Relationship between osteopontin and β-catenin immunohistochemical expression and prognostic parameters of colorectal carcinoma. Int J Clin Exp Pathol. 2015; 8(2): 1503-14.Revista Ciencias Biomédicas - 2018https://creativecommons.org/licenses/by-nc-sa/4.0http://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessEsta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.https://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/view/2711OsteopontinColorectal neoplasmsImmunohistochemistryOsteopontinaNeoplasias colorrectalesInmunohistoquímicaOsteopontina, una proteína involucrada en la progresión tumoral, y su participación en el desarrollo del carcinoma colorrectal.Osteopontin, a protein involved in tumor progression, and its participation in the development of colorectal carcinoma.Artículo de revistainfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1Textinfo:eu-repo/semantics/articleJournal articlePublicationOREORE.xmltext/xml2634https://repositorio.unicartagena.edu.co/bitstreams/3da2383d-7096-4acd-a5f6-74d5d0f80727/download17d8e66a148790fc683d5eabd5b3a347MD5111227/12866oai:repositorio.unicartagena.edu.co:11227/128662024-09-05 15:30:42.618https://creativecommons.org/licenses/by-nc-sa/4.0Revista Ciencias Biomédicas - 2018metadata.onlyhttps://repositorio.unicartagena.edu.coBiblioteca Digital Universidad de Cartagenabdigital@metabiblioteca.com

Publicaciones similares